Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Seeking Alpha / 13 minutes from now 1 Views
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25
Seeking Alpha / 13 minutes from now 1 Views
Comments